{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:00:30Z","timestamp":1781712030974,"version":"3.54.5"},"reference-count":75,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Peritoneal metastasis represents an aggressive disease pattern in pancreatic ductal adenocarcinoma (PDAC), traditionally associated with poor survival and limited therapeutic options. Emerging intraperitoneal chemotherapy strategies\u2014including hyperthermic intraperitoneal chemotherapy (HIPEC), normothermic intraperitoneal paclitaxel (NIPEC\/IP-PTX), and pressurized intraperitoneal aerosol chemotherapy (PIPAC)\u2014have been investigated to improve local tumor control and survival outcomes. Methods: We systematically reviewed published studies evaluating HIPEC, NIPEC\/IP-PTX, and PIPAC in PDAC, including adjuvant, cytoreductive, and palliative settings. Study characteristics, feasibility, perioperative outcomes, oncologic outcomes, and risk of bias were analyzed. Results: Across modalities, intraperitoneal treatment strategies demonstrated acceptable feasibility and safety profiles in appropriately selected patients. Adjuvant HIPEC following pancreatectomy showed reduced local\u2013regional recurrence signals in limited cohorts. CRS + HIPEC among patients with isolated peritoneal metastases yielded encouraging multi-year survival in highly selected candidates achieving complete cytoreduction. NIPEC\/IP-PTX demonstrated favorable ascites control, symptom relief, and potential conversion to resection in select patients. PIPAC was primarily used in unresectable, heavily pretreated, palliative peritoneal metastasis settings, with goals centered on disease stabilization, histologic regression, and symptom control rather than curative intent. Conclusions: Intraperitoneal chemotherapy strategies in PDAC appear feasible with signals of meaningful clinical benefit in select settings. While CRS + HIPEC may benefit carefully selected metastatic patients, NIPEC\/IP-PTX and PIPAC hold value primarily in symptom control and disease stabilization. Larger prospective trials are needed to define patient selection, optimize treatment protocols, and clarify survival benefit.<\/jats:p>","DOI":"10.3390\/cancers18020182","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:40:29Z","timestamp":1767692429000},"page":"182","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intraperitoneal Chemotherapy Strategies in Pancreatic Ductal Adenocarcinoma: A Systematic Review of Hyperthermic Intraperitoneal Chemotherapy, Normothermic Intraperitoneal Chemotherapy, and Pressurized Intraperitoneal Aerosol Chemotherapy"],"prefix":"10.3390","volume":"18","author":[{"given":"Nency","family":"Ganatra","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX 77701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdelhakeem","sequence":"additional","affiliation":[{"name":"Division of Haematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3115-5286","authenticated-orcid":false,"given":"Pragya","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baptist Hospitals of Southeast Texas, Beaumont, TX 77701, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saivaishnavi","family":"Kamatham","sequence":"additional","affiliation":[{"name":"Division of Haematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Elantably","sequence":"additional","affiliation":[{"name":"Division of Haematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwatayo","family":"Adeoye","sequence":"additional","affiliation":[{"name":"Division of Haematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani M.","family":"Babiker","sequence":"additional","affiliation":[{"name":"Division of Haematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6291-846X","authenticated-orcid":false,"given":"Conor D.","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"Division of Haematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Majeed","sequence":"additional","affiliation":[{"name":"Division of Haematology and Oncology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"ref_1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_5","first-page":"430","article-title":"Peritoneal metastases in pancreatic carcinoma","volume":"40","author":"Warshaw","year":"1993","journal-title":"Hepatogastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/gut.2010.226092","article-title":"Stromal biology and therapy in pancreatic cancer","volume":"60","author":"Neesse","year":"2011","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"Ohlund","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_9","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/nature09515","article-title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer","volume":"467","author":"Yachida","year":"2010","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","article-title":"Intraperitoneal antineoplastic drug delivery: Rationale and results","volume":"4","author":"Markman","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000658-198807000-00005","article-title":"Intraperitoneal Hyperthermic Perfusion Combined with Surgery Effective for Gastric Cancer Patients with Peritoneal Seeding","volume":"208","author":"Fujimoto","year":"1988","journal-title":"Ann. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sugarbaker, P.H. (1996). Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Peritoneal Carcinomatosis: Principles of Management, Springer.","DOI":"10.1007\/978-1-4613-1247-5"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chia, D.K.A., Demuytere, J., Ernst, S., Salavati, H., and Ceelen, W. (2023). Effects of Hyperthermia and Hyperthermic Intraperitoneal Chemoperfusion on the Peritoneal and Tumor Immune Contexture. Cancers, 15.","DOI":"10.3390\/cancers15174314"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2307\/3576524","article-title":"Inhibition by Hyperthermia of Repair Synthesis and Chromatin Reassembly of Ultraviolet-Induced Damage to DNA","volume":"100","author":"Bodell","year":"1984","journal-title":"Radiat. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e70059","DOI":"10.1111\/imr.70059","article-title":"Role of Fibroblast-Immune Crosstalk in Kidney, Lung, and Skin Tertiary Lymphoid Structures","volume":"334","author":"Cross","year":"2025","journal-title":"Immunol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jamcollsurg.2013.12.013","article-title":"Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1000 Patients","volume":"218","author":"Levine","year":"2014","journal-title":"J. Am. Coll. Surg."},{"key":"ref_18","first-page":"86","article-title":"Intraperitoneal paclitaxel in the management of ovarian cancer","volume":"22","author":"Markman","year":"1995","journal-title":"Semin Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1349-7006.2010.01747.x","article-title":"Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-con-butyl methacrylate) in peritoneal metastatic nodules","volume":"102","author":"Kamei","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1200\/JCO.1998.16.8.2620","article-title":"Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group Study","volume":"16","author":"Markman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_21","first-page":"S10","article-title":"S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis","volume":"5","author":"Kitayama","year":"2012","journal-title":"Gastrointest. Cancer Res. GCR"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","article-title":"Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases","volume":"28","author":"Saito","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.21037\/jgo-2020-03","article-title":"Intraperitoneal paclitaxel: Pharmacology, clinical results and future prospects","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/bjs\/znac284","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC): Updated systematic review using the IDEAL framework","volume":"110","author":"Baggaley","year":"2022","journal-title":"Br. J. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10585-020-10023-5","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) of peritoneal metastasis from gastric cancer: A descriptive cohort study","volume":"37","author":"Graversen","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejso.2018.05.020","article-title":"Occupational exposure to cisplatin\/oxaliplatin during Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)?","volume":"44","author":"Ametsbichler","year":"2018","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s00432-016-2234-0","article-title":"Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model","volume":"142","author":"Khosrawipour","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_29","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: A new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-06-2854","article-title":"The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses","volume":"13","author":"Deeken","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jclinepi.2019.11.018","article-title":"The clinical trial transparency in oncology significantly increased over the recent years","volume":"119","author":"Song","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J. Clin. Epidemiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Guyot, P., Ades, A.E., Ouwens, M.J.N.M., and Welton, N.J. (2012). Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 12.","DOI":"10.1186\/1471-2288-12-9"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/CLEP.S66677","article-title":"Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: The Newcastle\u2013Ottawa Scale and the RTI item bank","volume":"6","author":"Margulis","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.297.19.2077-b","article-title":"Analytic Approaches to Observational Studies with Treatment Selection Bias","volume":"297","author":"Vandenbroucke","year":"2007","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/acsnano.8b02481","article-title":"Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer","volume":"12","author":"Zhao","year":"2018","journal-title":"ACS Nano"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1007\/s12094-024-03837-2","article-title":"Clinical implications of epithelial-to-mesenchymal transition in cancers which potentially spread to peritoneum","volume":"27","author":"Carbone","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0304-3835(95)03743-G","article-title":"Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis","volume":"91","author":"Gardner","year":"1995","journal-title":"Cancer Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0140-6736(91)90201-Y","article-title":"Publication bias in clinical research","volume":"337","author":"Easterbrook","year":"1991","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ayorinde, A.A., Williams, I., Mannion, R., Song, F., Skrybant, M., Lilford, R.J., and Chen, Y.F. (2020). Assessment of publication bias and outcome reporting bias in systematic reviews of health services and delivery research: A meta-epidemiological study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0227580"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9086","DOI":"10.1245\/s10434-021-10254-0","article-title":"A Prospective, Phase I\/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma","volume":"28","author":"Yurttas","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"znaf076","DOI":"10.1093\/bjs\/znaf076","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with colon cancer at high risk of peritoneal metastases: Individual patient data meta-analysis","volume":"112","author":"Hamm","year":"2025","journal-title":"Br. J. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.ejso.2018.06.036","article-title":"Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis","volume":"44","author":"Caro","year":"2018","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1245\/s10434-022-12328-z","article-title":"Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study","volume":"30","author":"Grotz","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1245\/s10434-023-14138-3","article-title":"Oncologic Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Highly Selected Patients with Metastatic Pancreatic Ductal Adenocarcinoma","volume":"30","author":"Gudmundsdottir","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12957-024-03464-9","article-title":"Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with pancreatic cancer peritoneal metastasis","volume":"22","author":"Yan","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_50","first-page":"482","article-title":"Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer","volume":"23","author":"Tentes","year":"2018","journal-title":"J. BUON"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/SLA.0000000000001705","article-title":"Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel with S-1 for Pancreatic Ductal Adenocarcinoma Patients with Peritoneal Metastasis","volume":"265","author":"Satoi","year":"2017","journal-title":"Ann. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jhbp.447","article-title":"Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: A retrospective study in a single institution","volume":"24","author":"Satoi","year":"2017","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12029-014-9603-1","article-title":"Intravenous and Intraperitoneal Paclitaxel with S-1 for Refractory Pancreatic Cancer with Malignant Ascites: An Interim Analysis","volume":"45","author":"Takahara","year":"2014","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/bjs.11792","article-title":"Phase I\/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis","volume":"107","author":"Yamada","year":"2020","journal-title":"Br. J. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10637-020-00982-7","article-title":"A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis","volume":"39","author":"Takahara","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10585-018-9925-7","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastases of pancreas and biliary tract cancer","volume":"35","author":"Horvath","year":"2018","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2743985","DOI":"10.1155\/2018\/2743985","article-title":"Feasibility, Safety, and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Metastasis: A Registry Study","volume":"2018","author":"Kurtz","year":"2018","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1758835920940887","DOI":"10.1177\/1758835920940887","article-title":"Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma","volume":"12","author":"Sgarbura","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Robella, M., De Simone, M., Berchialla, P., Argenziano, M., Borsano, A., Ansari, S., Abollino, O., Ficiar\u00e0, E., Cinquegrana, A., and Cavalli, R. (2021). A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis. Cancers, 13.","DOI":"10.3390\/cancers13051060"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Khosrawipour, T., Khosrawipour, V., and Giger-Pabst, U. (2017). Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186709"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/02656736.2016.1227094","article-title":"The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer","volume":"32","author":"Tentes","year":"2016","journal-title":"Int. J. Hyperth."},{"key":"ref_62","first-page":"812","article-title":"Intraperitoneal chemotherapy of peritoneal carcinomatosis: Pharmacology, application rationale, and perspectives","volume":"40","author":"Kerb","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1245\/s10434-022-12723-6","article-title":"A Multicenter Phase 1 Trial Evaluating Nanoliposomal Irinotecan for Heated Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery for Patients with Peritoneal Surface Disease","volume":"30","author":"Choi","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Breusa, S., Zilio, S., Catania, G., Bakrin, N., Kryza, D., and Lollo, G. (2023). Localized chemotherapy approaches and advanced drug delivery strategies: A step forward in the treatment of peritoneal carcinomatosis from ovarian cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1125868"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1515\/pp-2024-0010","article-title":"Combined Nabpaclitaxel pressurized intraPeritoneal aerosol chemotherapy with systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases: Protocol of single-arm, open-label, phase II trial (Nab-PIPAC trial)","volume":"9","author":"Ferracci","year":"2024","journal-title":"Pleura Peritoneum"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e067691","DOI":"10.1136\/bmjopen-2022-067691","article-title":"Nab-PIPAC: A phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity","volume":"13","author":"Lang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5180895","DOI":"10.1155\/2019\/5180895","article-title":"Colorectal Peritoneal Metastases: A Systematic Review of Current and Emerging Trends in Clinical and Translational Research","volume":"2019","author":"Koumpa","year":"2019","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"103681","DOI":"10.1016\/j.esmoop.2024.103681","article-title":"Phase I PIANO trial\u2014PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: Clinical and translational outcomes","volume":"9","author":"Sundar","year":"2024","journal-title":"ESMO Open"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Safari, D., Fakhrolmobasheri, M., and Soleymanjahi, S. (2024). Efficacy and safety of intraperitoneal chemotherapy for pancreatic cancer. BMC Surg., 24.","DOI":"10.1186\/s12893-024-02526-9"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Wu, G., Standring, O.J., King, D.A., Gholami, S., Devoe, C.E., Thiels, C.A., Grotz, T.E., Weiss, M.J., Whelan, R.L., and Raoof, M. (2025). Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32020103"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"109499","DOI":"10.1016\/j.ejso.2024.109499","article-title":"Outcomes of intraperitoneal chemotherapy for the treatment of gastric cancer with peritoneal metastasis: A comprehensive systematic review and meta-analysis","volume":"51","author":"Boshier","year":"2024","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10555-020-09924-4","article-title":"Molecular mediators of peritoneal metastasis in pancreatic cancer","volume":"39","author":"Avula","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10585-021-10074-2","article-title":"The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: A systematic review","volume":"38","author":"Webb","year":"2021","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/182\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T09:45:25Z","timestamp":1767692725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/2\/182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":75,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18020182"],"URL":"https:\/\/doi.org\/10.3390\/cancers18020182","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]}}}